about
Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging conceptsChallenges of advanced hepatocellular carcinomaImaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in developmentAdvanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendationsDual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy.Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failurePazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience.New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to knowTherapeutic response in musculoskeletal soft tissue sarcomas: evaluation by MRI.Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT.Case Report: Jejunal gastrointestinal stromal tumour, a rare tumour, with a challenging diagnosis and a successful treatment.Appropriateness criteria of FDG PET/CT in oncology.Synchronous occurrence of gastrointestinal stromal tumors and other digestive tract malignancies in the elderly.Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECISTThe use of tumour volumetrics to assess response to therapy in anticancer clinical trialsBeyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?Treatment and Prognoses in Patients With Primary Gastrointestinal Stromal Tumors ≥10 cm: A Single-Institution Experience in China.The Therapeutic Response of Gastrointestinal Stromal Tumors to Imatinib Treatment Assessed by Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance Imaging with Histopathological Correlation.Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline.Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.Surgical treatment of gastric gastrointestinal stromal tumorEvaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma.Quantitative multimodality imaging in cancer research and therapyMonitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases.Survival and radiation risk in patients obtaining more than six CT examinations during one year.New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma.A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment.Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumabMedical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenibClinical applications of positron emission tomography in sarcoma management.Imaging assessment of tumor response: past, present and future.Imaging modalities of gastrointestinal stromal tumors.Advanced renal mass imaging: diffusion and perfusion MRI.Adjuvant therapy of gastrointestinal stromal tumors (GIST).MRI of the stomach: a pictorial review with a focus on oncological applications and gastric motility.Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.Small Intestinal and Mesenteric Multiple Gastrointestinal Stromal Tumors Causing Occult Bleeding
P2860
Q26863654-E9DCD350-8D18-4310-9A73-AE5FC59A4914Q28076867-CBEB05CA-139C-49A3-BB7F-A6CA9F365FA7Q28083433-ED2B9CDF-1E25-4BFE-80E6-E39EA65832B2Q28247449-36B3471C-2DB8-4585-B6FD-F014CD6C470EQ33588174-F155FCFC-BD04-4023-9BE4-4C522AE9AB71Q34029127-725D7022-4ED7-44F8-9ABB-D64F9186A44CQ34628804-F3DBD42E-0D32-4F11-BB3D-107689AA24F7Q35001643-BB4015D5-347E-4103-BF68-0647139FDDDDQ35060225-E0AE9934-93ED-4A95-AD28-835FEA6EFB97Q35093270-8595873D-3611-40CF-B07C-DD4DC4C9477BQ35148900-EF636F08-0A33-4EAB-BE68-86BD7055B32BQ35535875-D0785CED-DCD8-44A7-85EF-23E14A6D8D37Q35561995-86930B52-0679-4E2C-8E20-B7EB24B12FDBQ35568776-B228E68D-0BEA-48B6-BC22-5FE034490F92Q35781609-21FAA38D-0D8D-4BC5-BB41-4C92617F2226Q36015295-F50DA147-C213-4EF9-8E00-EE1827742585Q36081423-743B7A87-CF64-440C-B715-0FCEFCD1A8ACQ36125976-1D1A0359-5CC3-40D7-87DE-90CA3EB9BAD1Q36173335-9064D5E4-5194-4632-B8DC-F772E64FBE3BQ36196622-30EFD8D6-FE27-4C25-9F84-BF34128F37D1Q36211966-3375CCD1-0645-42E4-B273-8C4CEF8D5E4BQ36530034-CB72FF41-F7AB-4B2D-9003-0B6FF3951065Q36567385-ECE0A7C0-4D5B-4143-917E-0710EFF76DF4Q36770203-A61ABF45-17F0-47AD-9EDB-9ACC95C08AE1Q36907986-2B486C56-547A-4E3D-BE6D-CA3867E42855Q37007810-42CBE4BC-A475-46ED-B150-30999AC12F57Q37034519-DA0B9493-C7BD-447B-8AA9-35FE60A790B2Q37334162-16ED0EE8-525D-432D-988E-31FF654706D0Q37577930-4E92F46F-F3B6-42FD-84A2-F9A9B2C39153Q37606055-AABE2E03-C50B-4450-8D3D-F34762A13D12Q37701127-AC6C6BF6-79A2-4A49-9C4D-10AC7368261CQ37821302-5D99174C-ADA8-41B0-8A40-AF98A93400D3Q37845828-5013B4CE-9064-417B-9833-4942554CCDFBQ37875082-29626A24-DABB-4D4E-8C54-049FADAF2EF6Q37954208-1A01349F-2BB0-4262-BD1C-AC26BBD24E1FQ37955823-1B10A32F-0BE5-4B9C-A625-02BDC8EF6C95Q38022443-F19AB8E8-58FA-42AF-B8BF-5530C5C97817Q38254792-D1D30B46-1E4C-4371-A76B-0E7AE94B6D55Q38265024-A7577978-E4B8-41BD-9A5C-D8F3B660DE89Q38686060-ED20B818-E594-4A0B-AFDF-5B27867F5721
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Response evaluation of gastrointestinal stromal tumors.
@en
Response evaluation of gastrointestinal stromal tumors.
@nl
type
label
Response evaluation of gastrointestinal stromal tumors.
@en
Response evaluation of gastrointestinal stromal tumors.
@nl
prefLabel
Response evaluation of gastrointestinal stromal tumors.
@en
Response evaluation of gastrointestinal stromal tumors.
@nl
P1433
P1476
Response evaluation of gastrointestinal stromal tumors.
@en
P2093
Haesun Choi
P356
10.1634/THEONCOLOGIST.13-S2-4
P478
13 Suppl 2
P577
2008-01-01T00:00:00Z